NT5E and neoplasm: The exploratory biomarker analyses showed that patients with CD73-high tumours (CD73-positive expression in ≥50% TCs) who received the experimental treatment had a numerically higher ORR of 72.7% (95% CI, 39–94) compared with those in the control arm (35.7% [95% CI, 12.8–64.9]).